Inhibitors of mycobacterial ATP synthase, such as bedaquiline, TBAJ-587, TBAJ-876, squaramides, GaMF1, and DeMF1, break the energy metabolism and effectively inhibit Mtb, offering promising strategies against mycobacterial infections.
Schematic diagram illustrating the proposed mechanism for higher efficacy of combination therapy via a dual approach in managing drug-susceptible and MDR TB, contrasting with conventional drug therapy.
Mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase (NDH-2) transports electrons into the mycobacterial respiratory pathway at the cost of reduction of NADH to NAD+ and is an attractive drug target.
The identification of novel anti-tubercular agents capable of eliciting lethal responses against drug-resistant tuberculosis is critically needed to address the escalating mortality from tuberculosis.
Treatment of Mycobacterium tuberculosis infections is a challenging task due to long treatment regiments and a growing number of resistant clinical isolates.